http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 26 Feb 2026 16:41:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Dec+31/26072038.html si-local-file:///var/storage/secattach/20260226/26072038.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Dec+31/26072038.html Thu, 26 Feb 2026 16:41:00 -0500 O.13305050 PBYI http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Dec+31/26072038.html si-local-file:///var/storage/secattach/20260226/26072038.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Dec+31/26072038.html Thu, 26 Feb 2026 16:41:00 -0500 O.13305050 PBYI http://www.streetinsider.com/Earnings/Puma+Biotech+%28PBYI%29+Tops+Q4+EPS+by+2c+%3B+Offers+Guidance/26071371.html <p>Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.29, $0.02 better than the analyst estimate of $0.27. Revenue for the quarter came in at $75.5 million versus the consensus estimate of $66.6 million.</p><p><strong>GUIDANCE:</strong></p><p>Puma Biotech sees Q1 2026 revenue of $38-42 million, versus the consensus of $49 million.</p><p>Puma Biotech sees FY2026 revenue of $214-221 million, versus the consensus of $220 million.</p><p>For earnings history and earnings-related data on Puma Biotech (PBYI) <a href="http://www.streetinsider.com/ec_earnings.php?q=PBYI">click here</a>.</p> http://www.streetinsider.com/Earnings/Puma+Biotech+%28PBYI%29+Tops+Q4+EPS+by+2c+%3B+Offers+Guidance/26071371.html Thu, 26 Feb 2026 16:29:56 -0500 PBYI http://www.streetinsider.com/Guidance/Puma+Biotech+%28PBYI%29+Tops+Q4+EPS+by+2c+%3B+Offers+Guidance/26071371.html <p>Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.29, $0.02 better than the analyst estimate of $0.27. Revenue for the quarter came in at $75.5 million versus the consensus estimate of $66.6 million.</p><p><strong>GUIDANCE:</strong></p><p>Puma Biotech sees Q1 2026 revenue of $38-42 million, versus the consensus of $49 million.</p><p>Puma Biotech sees FY2026 revenue of $214-221 million, versus the consensus of $220 million.</p><p>For earnings history and earnings-related data on Puma Biotech (PBYI) <a href="http://www.streetinsider.com/ec_earnings.php?q=PBYI">click here</a>.</p> http://www.streetinsider.com/Guidance/Puma+Biotech+%28PBYI%29+Tops+Q4+EPS+by+2c+%3B+Offers+Guidance/26071371.html Thu, 26 Feb 2026 16:29:56 -0500 PBYI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Feb+26/26071355.html si-local-file:///var/storage/secattach/20260226/26071355.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Feb+26/26071355.html Thu, 26 Feb 2026 16:25:00 -0500 O.13305050 PBYI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Feb+26/26071355.html si-local-file:///var/storage/secattach/20260226/26071355.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PUMA+BIOTECHNOLOGY%2C+INC.++For%3A+Feb+26/26071355.html Thu, 26 Feb 2026 16:25:00 -0500 O.13305050 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2025 compared to the fourth quarter and full year 2024. </p><p> Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma’s first commercial product. Product revenue, net in the fourth quarter of 2025 was $59.9 million, compared to $54.4 million in the fourth quarter of 2024. Product revenue, net for the full year 2025 was $204.1 million, compared to $195.2 http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Reports+Fourth+Quarter+and+Full+Year+2025+Financial+Results/26070365.html Thu, 26 Feb 2026 16:05:00 -0500 A.06822034 A.60012004 O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:30 p.m. ET on Monday, March 2, at the TD Cowen 46th Annual Health Care Conference. The conference will be held March 2–4, 2026 at the Boston Marriott Copley Place in Boston. </p><p> A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pumabiotechnology.com&amp;esheet=54431561&amp;newsitemid=20260223106044&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.pumabiotechnology.com&amp;index=1&amp;md5=9f0ef6e0cf6aa70f87300752423954e5" shape="rect">https://www.pumabiotechnology.com</a>. The presentation will be archived on the website http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+to+Present+at+TD+Cowen%E2%80%99s+46th+Annual+Health+Care+Conference/26043441.html Mon, 23 Feb 2026 16:15:00 -0500 A.06822034 A.50100012 A.50216698 A.60012004 O.01304637 O.04148957 O.07579093 O.13305050 O.20026344 PBYI